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Abstract 
Consumers have begun to take a more proactive approach to their healthcare by accessing 
pharmaceutical companies Websites to obtain health and drug information. In exchange for 
these benefits, companies require consumers to voluntarily disclose information. However, 
research has shown that consumers continue to be concerned about how their information is 
managed, used, and distributed by companies, especially if accessed via the Web. To date, there 
has been limited empirical research to examine the actual online practices of companies when it 
comes to privacy, especially those of pharmaceutical companies. Using the Delphi expert panel 
process, we identified the components of a hierarchical benchmarking index to examine the 
documented and actual online practices of 100 Website registrations with pharmaceutical 
companies. In this paper, we outline the development of an index to measure the personal 
information privacy violations of pharmaceutical companies using hierarchical linear technique. 
Second, we provided empirical evidence regarding the magnitude of voluntary adherence to the 
Fair Information Practices (FIPs) by pharmaceutical companies based upon the personal 
information privacy violations. Our results revealed that companies with headquarters in Europe 
had fewer personal information privacy violations than those in the US. Moreover, our results 
indicate that fewer personal information privacy violations occur for chronic conditions than for 
non-chronic conditions, as well as fewer violations occur with Website registrations for updates 
than for discounts. Finally, both Europe and UK demonstrated more overall adherence to the 
FIPs than the US and Asia. This suggests that self-regulation may not be sufficient, while more 
enforcement may be necessary to decrease personal information privacy violations.   
Keywords: Personal information privacy violations; Consumer control; Fair information 
practices; Information privacy; Information sharing; Pharmaceutical companies’ online 
practices; Hierarchical privacy index development 
Introduction 
The technological advancement of the Internet has revolutionized the way companies interact 
with consumers by enabling the ability to collect, store, transfer, sell, and analyze consumer 
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information (Lanier & Saini, 2008; Rapp, Hill, Gaines, & Wilson, 2009; Xu, 2009). Companies 
are able to leverage the Internet to establish relationships with consumers through the selling of 
products and services or to be a source of information. However, in order to establish this 
relationship and engage in target marketing, companies must collect information either by 
voluntary or involuntary methods (Christiansen, 2011). According to Christiansen (2011), “a 
user’s voluntary sharing of such information” (p. 509) is considered voluntary disclosure and one 
of the methods of collecting information. Christiansen (2011) also noted that involuntary 
methods are malicious and “involve the use of technology to collect data and track movements 
by Internet users without their knowledge and/or permission” (p. 511). Once the information is 
collected, the storage, access, and distribution are managed by the company (Milne, Rohm, & 
Bahl, 2004). As a result, the information becomes at risk for secondary use, unauthorized access, 
and sharing with third parties (Milne et al., 2004). Hoffman, Novak, and Peralta (1999) defined 
secondary use as “the use of personal information for other purposes, subsequent to the 
transaction where the information was originally collected” (p. 131). In the same context, Culnan 
and Armstrong (1999) defined information sharing as “sharing personal information with others 
who were not a party to the original transaction” (p. 106). With the increase use of Web-based 
systems, companies’ online practices of information sharing (OPIS) are proliferating, and so 
does risks related to the privacy of such information. Because of the information sharing risks by 
companies, the online practices of consumer control (OPCC) are important to consumers (Liu, 
Marchewka, Lu, & Yu, 2005). Hoffman et al. (1999) defined consumer control as “the 
consumer’s ability to control the dissemination of information related to or provided during such 
transactions or behaviors to those who were not present” (p. 131). Liu et al. (2005) further noted 
that consumers expect to maintain some level of control over how their information is used and 
distributed.   
 
Because of the aforementioned risks, consumers are exposed to threats, such as identity theft and 
unsolicited marketing, which contribute to an elevation of consumer personal information 
privacy concerns (Zorotheos & Kafeza, 2009). As a result, consumers are hesitant to provide 
personal information via the Internet (Nam, Song, Lee, & Park, 2006). Likewise, Lanier and 
Saini (2008) noted that, while consumers appreciate the convenience and benefits of various 
technological advancements, they are concerned about how information collection practices 
impact their privacy. Therefore, some consumers take prudent actions such as decreasing Internet 
use, fabricating or falsifying information, and refusing to disclose information (Cromer, 2010; 
Yang & Wang, 2009). In this respect, Meinert, Peterson, Criswell, and Crossland (2006) noted 
that e-commerce suffered an approximate $15 billion in unrealized revenue due to lack of 
consumer trust regarding companies’ ability to protect or use their personal information in an 
ethical manner. In an effort to alleviate consumer concerns, companies post privacy seals and 
privacy policies on their Website to provide awareness of their information handling practices 
(Pollach, 2007). Jafarr and Abdullat (2009) defined the documented practices of the privacy 
policy (DPPP) as a “written, published statement that articulates the policy position of an 
organization on how it handles the personally identifiable information that it gathers and uses in 
the normal course of business” (p. 126). Regardless of privacy seals and DPPP, consumers 
expect companies to have an ethical responsibility to engage in practices that maintain 
information integrity and protect consumer information from unauthorized disclosure, access, 
Online Journal of Applied Knowledge Management 
A Publication of the International Institute for Applied Knowledge Management 
Volume3, Issue 2, 2015 
 
 
70 
 
use, or loss (Peltier, Milne, & Phelps, 2009). Moreover, this expectation is heightened for 
financial, medical, and health information (Gupta, Iyer, & Weisskirch, 2010; Yang & Wang, 
2009). Therefore, given the significant rise in the use of healthcare Websites (Davis, 2012; Kim 
& King, 2009) and the sensitivity of information, pharmaceutical companies’ Websites, the focus 
of this research study is to investigate the documented and actual online practices that are 
contributing to the proliferation of online privacy violations by pharmaceutical companies.  
 
In this paper, we outline our research study that developed a hierarchical benchmarking 
instrument to assess the documented and actual online practices implemented by pharmaceutical 
companies’ Websites. Using hierarchical linear technique of multiple measures, we derived a 
single composite index that represents an assessment of personal information privacy violations. 
The Personal Information Privacy Violations Index (PIPVI) hierarchical benchmarking 
instrument was used to compare the practices implemented from 100 Website registrations of 
pharmaceutical companies that market prescription medication for chronic and non-chronic 
conditions. We have selected these two sub-categories of the pharmaceutical market, as both 
appear to have a significant market share and appear to collect personal information, which a 
breach of such personal information can cause substantial embarrassment or even harm to 
individuals. For example, revealing the names of elected official who is taking some mental or 
other disorder medications can certainly be harmful for their reputation to remain in office. Thus, 
the main research problem that this study addressed is the proliferation of online privacy 
violations by companies (Anton, Earp, & Young, 2010; Li, Sarathy, & Xu, 2011; Nam et al., 
2006; Peltier et al., 2009).  
Theoretical Background 
The key theoretical foundation for this research study draws on the social exchange theory 
(SET). The context of the SET is that there is a voluntary exchange between multiple parties. 
Homans (1958) noted that “persons that give much to others try to get much from them, and 
persons that get much from others are under pressure to give much to them” (p. 606). The SET 
posits that consumers engage in a “privacy calculus” where they assess information disclosure 
against the expected benefits (Emerson, 1976). During the assessment, consumers evaluate if 
their information will be used ethically and if they will not suffer negative consequences from 
information disclosure (Xu, 2009). Yang and Wang (2009) used the SET to examine cost-benefit 
effects on privacy concern and behavioral intention. They found that privacy concern has a 
negative effect on information disclosure but a positive effect on privacy intention. In order to 
make an informed decision, the consumer should have prior knowledge of companies’ 
information practices (Xu, 2009). 
 
According to Westin (1967), information privacy is defined as “the right of individuals, groups, 
or institutions, to determine for themselves when, how, and to what extent information about 
them is communicated to others” (p. 7). Jafar and Abdullat (2009) noted that “the personal 
information privacy of an individual is violated when electronic personal information that was 
entrusted to third parties is electronically shared or crossed referenced with other parties without 
the consent of the individual” (p. 126). Specifically, consumers continue to be concerned with 
unsolicited email, identity theft, and negligent information loss through the selling and 
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unauthorized use of their information when using the Internet (Anton et al., 2010; Lanier & 
Saini, 2008; Pollach, 2007). Therefore, prior to disclosing information consumers engage in a 
risk-benefit analysis to evaluate if the benefit of the transaction surpasses the risk of information 
disclosure (Xu, 2009; Yang & Wang, 2009). This behavior is consistent with the value and 
stimulus propositions of the Social Exchange Theory (SET). The value proposition noted that 
“the more valuable to a person is the result of his action, the more likely he is to perform the 
action” (Emerson, 1976, p. 340). The stimulus proposition noted that: 
 
If in the past the occurrence of a particular stimulus, or set of stimuli, has been the 
occasion on which a person's action has been rewarded, then the more similar the present 
stimuli are to the past ones, the more likely the person is to perform the action, or some 
similar action now. (Emerson, 1976, p. 339)  
 
In other words, Emerson (1976) noted that if consumers perceive that the expected benefit 
prevails over the risk of information disclosure, they would voluntarily disclose the information. 
Likewise, if consumers have previously disclosed information and received the reward without 
perceptions of personal information privacy violation, they will be more willing to disclose 
information in similar conditions (Emerson, 1976). However, Nam et al. (2006) noted that 
“media scrutiny of Internet fraud, hacking, and identity theft has heightened people’s awareness 
of the risks of conducting transactions on the Internet” (p. 212). 
 
Identity theft and other personal information privacy violations in the United States (US) have 
continued to rise and receive media attention. For instance, Federal Trade Commission (FTC) 
(2013) reported that in 2012 identity theft was the top consumer complaint with 369,212 
incidents. The Privacy Rights Clearinghouse (2013) reported that since 2005 there have been 
932,729,111 records breached containing personal information from 4,478 reported incidents. 
Meanwhile, the Internet Crime Complaint Center (IC
3
) (2014) noted that over three million 
incidents have been reported since 2000. It is important to note that IC
3
 reported that the first 
million complaints occurred over seven years with the next million occurring in 3.5 years, 
indicating a significant escalation in cyber crimes each year. The IC
3
 (2010) indicated that a 
substantial number of complaints are due to loss of personally identifiable information (PII). 
Culnan and Armstrong (1999) defined PII as “information identifiable to an individual” (p. 105). 
The aforementioned incidents are significant indicators of the growth and occurrence of personal 
information privacy violations occurring through the use of the Internet and are key contributors 
to the escalation of consumer concerns (Lanier & Saini, 2008; Zorotheos & Kafeza, 2009).  
 
In response to the reoccurrence of personal information breaches in the US, the FTC established 
or adopted laws and regulations to protect consumers. The Fair Information Practices (FIPs) are 
“global principles that fairly balance the need for business to collect and use personal 
information with the legitimate privacy interests of consumers to be able to exercise control over 
the disclosure and subsequent uses of their personal information” (Milne & Culnan, 2002, p. 
345). FIPs are generally contained in a Website’s DPPP. However, enforcement of the FIPs 
occurs through self-regulation (Lanier & Saini, 2008; Nemati & Dyke, 2009; Xu, 2009). 
According to Xu (2009), “self-regulation involves the setting of standards by an industry group 
Online Journal of Applied Knowledge Management 
A Publication of the International Institute for Applied Knowledge Management 
Volume3, Issue 2, 2015 
 
 
72 
 
or certifying agency and the voluntary adherence to the set of standards by members or 
associates” (p. 24). In other words, companies are responsible for voluntarily compliance with 
these laws and regulations (Nemati & Dyke, 2009). Despite the existence of a Website’s DPPP 
and other US laws and regulations, the FTC (2013) noted that it continues to address cases of 
personal information privacy violations in the US with multi-million dollar settlements. 
Although consumer concerns are increasingly rising, so does Internet use, which implies that 
consumers are being more meticulous about interaction with particular Websites (Cromer, 2010). 
For instance, Nam et al. (2006) noted that the use of the Internet as an informational source has 
surpassed the purchasing of products. In this respect, as consumers begin to take a more 
proactive approach to their healthcare, the use of the Internet to obtain medical drug information 
is also on the rise (Davis, 2012). Davis (2012) indicated that the Internet is the second most used 
source for prescription drug information after healthcare physicians. However, Davis (2012) 
further noted that consumers prefer pharmaceutical companies’ Websites as a primary source of 
information. Kim and King (2009) noted that consumer’s access of pharmaceutical companies’ 
Websites tripled from 2000 to 2003. This proliferation is supported by Joseph, Spake, and 
Finney (2008) who also noted that less than 10% of consumers indicated physicians should be 
the primary source for pharmaceutical information. This is evident by consumer use of 
pharmaceutical companies’ Websites to access health and drug information, support groups, free 
drug samples, and rebates (Sheehan, 2005). It is important to note that to acquire those benefits 
consumers are required to disclose personal information. Equally important, consumers are more 
cautious about disclosing personal information with health Websites due to the sensitivity of 
information that may be required and the risk of companies developing inferences using 
information collected. For example, Bansal, Zahedi, and Gefen (2010) noted that personal health 
information could be used by employers or insurance agencies to discriminate against 
consumers. Therefore, it is important for consumers to understand the documented and actual 
online practices of any company they interact with (Milne, Rohm, & Bahl, 2004; Van Dyke, 
2007). Thus, additional research of the online information practices of Websites is warranted to 
understand the practices that are contributing to the proliferation of online privacy violations by 
companies (Lanier & Saini, 2008).  
Research Questions and Hypotheses 
Our main goal in this research study was to develop the Personal Information Privacy Violation 
Index (PIPVI) benchmarking instrument based on a hierarchical composition of the documented 
practices of the privacy policy measure (DPPPM), online practices of information sharing 
measure (OPISM), and the online practices of consumer control measure (OPCCM) to derive the 
PIPVI.  Davis (2012) noted that consumers use the Internet as source for medical information in 
addition to their physician. Kim and King (2009) also asserted that “Internet sources are more 
important for prescription drugs than for non-prescription drugs” (p. 5). Based upon the growth 
projections for the chronic and non-chronic prescription medication markets, it is expected that 
consumer use of pharmaceutical Websites will continue to rise. Therefore, it is important to 
understand the documented and actual online information practices of pharmaceutical companies 
to gain insight into how they use the information collected through their Websites. Our 
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expectation was that with the use of actual counting of violations, as opposed to perception-
based survey, our research study provides insight into the practices that are contributing to PIPV. 
Given the heightened concerns of consumers regarding personal information privacy, the results 
of this research study provides consumers with empirical evidence of how information is 
managed and used by pharmaceutical companies. Consumers will be able to assess the 
magnitude of information sharing and ability (or lack thereof) to control their information. A 
high magnitude of personal information privacy violations could negatively impact consumers’ 
trust, concerns, and interactions with the Websites, which could continue to constrain the growth 
of e-commerce. Because enforcement of the FIPs occurs through self-regulation, the results of 
this research study provide evidence regarding the magnitude of voluntary adherence to the FIPs 
by pharmaceutical companies. This evidence can assist advocacy groups and regulators with 
understanding the effectiveness of self-regulation. Furthermore, it can aide in determining if 
more stringent laws and regulations or enforcement is necessary. In addition, companies can use 
the PIPVI benchmarking instrument to perform a self-assessment of their Website documented 
and online practices, while seeing how these differ or change over time.  
 
We have set eight research questions and three hypotheses for this research study. Figure 1 
represents the conceptual model for the PIPVI. 
RQ1a: What are the experts’ approved components of the DPPP implemented by 
pharmaceutical companies using a Delphi expert methodology?   
RQ1b: What are the experts’ approved weights of the DPPP’s components implemented 
by pharmaceutical companies using a Delphi expert methodology?   
RQ2a: What are the experts’ approved components of the OPIS implemented by 
pharmaceutical companies using a Delphi expert methodology?   
RQ2b: What are the experts’ approved weights of the OPIS’s components implemented 
by pharmaceutical companies using a Delphi expert methodology? 
RQ3a: What are the experts’ approved components of the OPCC implemented by 
pharmaceutical companies using a Delphi expert methodology?   
RQ3b: What are the experts’ approved weights of the OPCC’s components implemented 
by pharmaceutical companies using a Delphi expert methodology? 
RQ4: What are the experts’ approved weights of the single, integrated, hierarchical 
measure of PIPVI’s components of DPPP, OPIS, and the OPCC implemented by 
pharmaceutical companies using a Delphi expert methodology? 
RQ5: Are there any statistical significance mean differences for DPPM between 
pharmaceutical companies that headquarters are based in United States versus 
Europe, Asia, or United Kingdom? 
RQ6: Are there any statistical significance mean differences for OPISM, OPCCM, and 
PIPVI between pharmaceutical companies that a) market chronic versus non-
chronic prescription medications, b) market registrations for prescription 
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medication discounts versus updates, c) their headquarters are based in United 
States, versus Europe, Asia, or United Kingdom?  
RQ7: Are there any significant differences between the documented and the actual online 
practices for choice, and access of pharmaceutical companies that a) market chronic 
versus non-chronic prescription medications, b) market registrations for prescription 
medication discounts versus updates, c) their headquarters are based in United 
States, versus Europe, Asia, or United Kingdom? 
RQ8: Are there any statistical significance mean differences for OPISM, OPCCM and 
PIPVI between pharmaceutical companies that collect a limited amount of PII and 
those that collect a high amount of PII? 
  H1: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will not be 
significantly different when controlling for company size.  
  H2: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will not be 
significantly different when controlling for annual revenue. 
  H3: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will not be 
significantly different when controlling for years in existence. 
 
 
Figure 1: Conceptual Model for Personal Information Violation Index (PIPVI) 
Methodology 
Our research study developed the PIPVI hierarchical benchmarking instrument that was used to 
assess the documented and actual online practices using data collected to develop a comparison 
report based upon 100 Website registrations of 25 pharmaceutical companies that market chronic 
and non-chronic prescription medications. See Table 1 for pharmaceutical company and Website 
demographics. Three phases were used to achieve the research goal. The first phase included the 
development and validation of the PIPVI hierarchical benchmarking instrument using the Delphi 
expert methodology. Dalkey and Helmer (1963) noted that the Delphi expert methodology’s 
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objective is “to obtain the most reliable consensus of opinion of a group of experts” (p. 458). 
Sarlak and Aliahmadi (2008) further stated that “the notion is that well informed individuals, 
calling on their insights and experience, are better equipped to predict the future than theoretical 
approaches or extrapolation of trends” (p. 1468). The Delphi expert methodology requires 
recurring elicitation from the expert panel using a questionnaire or interview to eliminate direct 
disagreement among the expert panel (Dalkey & Helmer, 1963). Ramim and Lichvar (2014) 
indicated that “the Delphi methodology is mainly used in the situation where accurate 
information is unavailable and human judgment input is crucial” (p. 127).  For our expert panel, 
at least 35 individuals from academia and practitioners in the fields of information security, 
privacy, as well as corporate social responsibility was solicited to participate from professional 
contacts with those associated to this research project as well as membership in professional 
society mailing lists. The expert panel was requested to evaluate the documented and online 
practices criteria, as well as assess the relative importance of each criterion in DPPP, OPIS, and 
OPCC. The relative importance of each criterion within each measure (DPPPM, OPISM, & 
OPCCM) was combined to develop the PIPVI. After consensus was achieved through several 
iterations with the expert panel, the feedback was incorporated to create the final PIPVI 
hierarchical benchmarking instrument based on the weights and validity of the criteria. The 
second phase used the Delphi-based developed PIPVI benchmarking instrument to assess the 
documented and actual online practices implemented from 100 Website registrations of 
pharmaceutical companies that market chronic and non-chronic prescription medications. In 
addition, the demographic information collected for each pharmaceutical company was used to 
assess if there are any significant differences in the pharmaceutical company's PIPVI, DPPPM, 
OPISM, and OPCCM based on its headquarters country/region, company size, annual revenues, 
condition type (chronic vs. non-chronic), and registration type (discount vs. update). To assess 
the pharmaceutical company’s DPPP, a copy of the privacy policy was downloaded and analyzed 
against the FIPs. To assess OPIS and OPCC, registration for a newsletter, update, discount, or 
support program was initiated with a unique name and email address for each Website 
registration. This enabled an assessment of the types of PII collected, information sharing, 
consumer choice, and access practices for each pharmaceutical company Website. The use of a 
unique name and email address for each Website registration maintained data integrity and 
facilitated accurate descriptive metrics for each. Otherwise, it would have been a potential 
challenge to determine accurate metrics for the origination of emails to assess information 
sharing for each pharmaceutical company Website. The third phase was to prepare a comparison 
report using the data collected in the PIPVI benchmarking instrument from 100 Website 
registrations of pharmaceutical companies that market chronic and non-chronic prescription 
medications. 
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Table 1 
Pharmaceutical Company and Website Demographics 
    Condition Type Registration Type 
Headquarters 
Country/Region 
n  % 
 
Website 
Registrations 
Chronic Non-
Chronic 
Discount Update 
 
Asia 2 8% 8 6 2 6 2 
Europe 6 24% 37 24 13 15 22 
United Kingdom 1 4% 5 0 5 3 2 
United States 16 64% 50 19 31 24 26 
Totals 25 100% 100 49 51 48 52 
 
 
Instrument Validity and Reliability 
 
According to Creswell (2002), “content validity is the extent to which the questions on the 
instrument and the scores from the questions are representative of all the possible questions that 
could be asked about the content or skills” (p. 184). Creswell (2002) defined validity as the 
researcher’s ability to “draw meaningful and justifiable inferences from scores about a sample or 
population” (p. 185). Sekeran (2003) further noted that “validity ensures the ability of a scale to 
measure the intended concept” (p. 206). Creswell (2002), Sekeran (2003), and Straub (1989) 
indicated that a panel of judges or experts could be used to validate the instrument content.  
 
Reliability is important because it indicates the extent of un-bias and is an indication of stability 
and consistency (Sekeran, 2003). Straub (1989) contended that it is important to show evidence 
that the instrument is measuring what it intends to measure, i.e. reducing threats to internal 
validity. McFadzean, Ezlingeard, and Birchall (2011) noted that the Delphi expert methodology 
“ensures that the data collection process is both reliable and valid because it exposes the 
investigation to differing, and often divergent, opinions and seeks convergence through 
structured feedback” (p. 108). Therefore, to ensure both validity and reliability, in this research 
study, we elicited feedback from the expert panel to verify that the criteria used to generate the 
measures were appropriate to assess the documented and online practices. 
 
Data Analysis 
 
The data collected was first subjected to pre-analysis data preparation, where it was examined for 
accuracy in preparation for analysis (Levy, 2006; Mertler & Vannatta, 2010). The first data set 
from the expert panel was tabulated in the data screening process. Those values were placed into 
a table with responses from each expert panelist that represents their preference for the DPPP, 
OPIS, and OPCC criteria and weights. Following the initial data entry tabulation, one more 
researcher reviewed the records to ensure accuracy. Afterwards the mean was computed for each 
weight. It is important to note that the combined weights must total 100%, as the focus of the 
index is to evaluate the distribution of importance across all criteria measured. The second data 
set from the PIPVI benchmarking instrument was collected from the 100 Website registrations of 
pharmaceutical companies that market chronic and non-chronic prescription medications. Those 
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values were placed into a table with responses for each Website registration for the 
pharmaceutical company. Once observed values were tabulated, they were divided by the total 
number of criteria for DPPP, and OPCC. For OPIS, the observed values were divided by the 
maximum number of emails.  Afterwards, the values were multiplied by the Delphi expert panel 
approved weight for each criterion to compute the measures DPPPM, OPISM, and OPCCM. 
These calculated measures were then multiplied by the expert panel approved weights and 
combined to derive the hierarchical PIPVI for the sample of registrations for the pharmaceutical 
company Websites. The calculated PIPVI was used to sort the data and compute the standard 
deviation (SD), which was used to develop the comparison report to address the research 
questions and hypothesis (See Eq. 1, 2, 3, & 4). Next, statistical tests, such as factorial analysis 
of variance (ANOVA) was conducted to further compare the data based upon the pharmaceutical 
companies condition types (chronic vs. non-chronic), registration types (updates vs. discounts), 
and headquarters country/region (Asia, Europe, United Kingdom, & United States), which 
addressed research questions five and six. Additional statistical tests, such as factorial analysis of 
variance (ANOVA), factorial analysis of covariance (ANCOVA), chi-square, and Spearson 
correlation were conducted to further compare the data based upon the pharmaceutical 
company’s documented versus actual practices, PII collection, its headquarters country/region, 
company size, and reported annual revenue to assess any significant differences in the PIPVI. 
These analyses addressed research questions seven, eight, and all three hypotheses. Figure 2 
depicts how the index value was derived from the three measures and the germane criteria for 
each measure. 
 
 
Figure 2: Hierarchical View of the Index, Measures, and Criteria of PIPVI 
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Results 
The results for our research study are three folds. First, the research study was conducted with an 
expert panel using the Delphi Method in early June, 2014 and concluded late September, 2014. 
The expert panel was solicited by email, and professional society mailing lists. Second, after data 
collection from the 100 Website registrations, our results revealed if there are statistical mean 
differences in PIPVI, DPPPM, OPISM, and OPCCM between pharmaceutical companies that 
market chronic and non-chronic prescription medications. Last, the results revealed if there were 
any significant differences in the pharmaceutical company's PIPVI, DPPPM, OPISM, and 
OPCCM based on headquarter country/region, company size, and annual revenues.  
 
To answer the first four research questions, the expert panel participated in two rounds using the 
Delphi Method. In the first round, the expert panel was solicited to validate that the proposed 
measures and criteria were sufficient to measure personal information privacy violations, in 
addition to eliciting the relative weight allocations. An email that contained a link to a Web-
based survey tool was used to record the opinions of the expert panel using a survey instrument.  
Twenty-five participants completed the first survey and no responses were omitted. The expert 
panel was requested to specify their level of agreement for the measures and criteria based upon 
on a Likert scale from 1 = strongly disagree to 7 = strongly agree. The level of agreement for at 
least somewhat agreed (5) or above ranged from 68% to 96%. After assessment of the comments 
from the expert panel, capturing the volume of phone calls/text messages were added to the 
criteria for OPIS to assess secondary and third party use. Because the comments were general in 
nature pertaining to the measures, criteria, and practices, no further additions were warranted.  
 
After the mean was calculated from the relative weights suggested by the expert panel in the first 
round, the second round of the survey was to elicit responses to validate the relative weights 
were sufficient for the measures and criteria using a nominal scale with levels: no (0) and yes (1). 
For this round, 23 participants completed the survey. After tabulation of the survey responses, 
two responses regarding the weight allocations for DPPPM criterion were omitted for the DPPP 
because the recommended weight distribution did not total 100%. In this round, the level of 
agreement for this survey ranged from 48% to 78%.  For the level of agreement between 48% 
and 65%, the suggested mean weights for those that did not agree were within 5% of the 
proposed weight. Therefore, the proposed weight was determined to be sufficient, and additional 
rounds were not conducted. See Table 2 for the final weight allocations based upon the expert 
panel’s opinion.  
 
Table 2 
PIPVI Criteria, Measures, and Weights Results from the Delphi Expert Panel  
DPPP OPIS OPCC PIPVI 
Notice Choice Access Security Choice Access Choice Access DPPPM OPISM OPCCM 
25% 22% 20% 33% 55% 45% 58% 42% 35% 33% 32% 
100% 100% 100% 100% 
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To examine the fifth research question, differences in the DPPPM scores by headquarters 
country/region were examined. When the ANOVA was conducted for the DPPPM scores by 
headquarters country/region, the results were not significant, F(3, 21) = 1.86, p = 0.168, partial 
η2 = 0.21. This suggests that there were no significant differences in DPPPM scores by 
headquarters country/region. For the sixth research question, the ANOVAs for OPISM, OPCCM, 
and PIPVI scores by condition type, registration type, and headquarters country/region were 
examined. No significant differences were found in the OPISM scores. However, significant 
differences were found in OPCCM scores by condition type, F(1, 58) = 5.25, p = 0.026, partial 
η2 = 0.08, suggesting that OPCCM scores for chronic conditions tended to be significantly lower 
than scores for non-chronic conditions. These scores suggest that consumers appear to have more 
control over their data for chronic conditions than for non-chronic conditions. No other 
significant differences were found in the OPCCM scores. Significant differences were found in 
PIPVI scores by condition type, F(1, 98) = 11.76, p = 0.001, partial η2 = 0.11, suggesting that 
PIPVI scores for chronic conditions were significantly lower than scores for non-chronic 
conditions. These scores appear to suggest that fewer personal information privacy violations 
occur for chronic conditions than for non-chronic conditions. PIPVI scores were also 
significantly different by registration type, F(1, 98) = 5.12, p = 0.026, partial η2 = 0.05, 
suggesting that PIPVI scores for discount registration types were significantly higher than update 
PIPVI scores. These scores appear to suggest that more violations occur with Website 
registrations for discounts than for updates. Finally, PIPVI scores were significantly different by 
headquarters country/region, F(3, 96) = 6.48, p < 0.001, partial η2 = 0.17. Post hoc pairwise 
comparisons showed that European PIPVI scores tended to be significantly lower compared to 
the US PIPVI scores. These results appear to suggest that European countries might be more 
responsible with management and use of consumer personal information.  
 
To examine the seventh research question, the chi-square analyses (χ2) for documented versus 
actual practices were examined by condition type, registration type, and headquarters 
country/region. A significant difference between documented versus actual practices for the 
ability to opt-in/opt-out of secondary use after the initial registration and headquarters 
country/region was found, χ2(6) = 20.20, p = 0.003.  Further examination showed that Europe 
had a higher level of documented versus actual practices agreement for this criterion than any 
other headquarters country/region. A significant difference between documented versus actual 
practices for the ability to opt-in/opt-out of third party use after the initial registration and 
headquarters country/region was found, χ2(6) = 14.19, p = 0.028. Next, a significant difference 
between documented versus actual practices for the ability to review personal information and 
headquarters country/region was found, χ2(6) = 17.84, p = 0.007. However, for opt-in/opt-out of 
third party use after the initial registration and ability to review personal information, expected 
values were found to be below 1.00, and, thus, caution should be taken in the interpretation and 
generalization of the chi-square results. Although significance was found, no large differences 
between the actual and documented values were found in the chi-square. This suggests that there 
were slight differences between the documented and actual values for all countries, but no major 
differences. Results of the chi-squares showed a significant difference between documented 
versus actual practices for the ability to modify personal information and headquarters 
country/region, χ2(6) = 20.46, p = 0.002. There were more European pharmaceutical companies 
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with agreement between documented versus actual practices for the ability to modify personal 
information. There were fewer US pharmaceutical companies with agreement between 
documented versus actual practices for the ability to modify personal information than expected. 
Moreover, there were more violations for documented practices by US pharmaceutical 
companies for the ability to modify personal information than other countries. Next, the results 
of the chi-square analysis showed a significant difference between documented versus actual 
practices for the ability to delete personal information and headquarters country/region, χ2(3) = 
9.35, p = 0.025. Because the Asian pharmaceutical companies in our study did not have 
documented practices for delete or provide the ability to delete personal information, they had 
more agreement between documented and actual practices for the ability to delete personal 
information than the other countries. All other chi-square analyses for condition type and 
registration type were not significant.   
 
To examine the eighth research question, additional ANOVAs were conducted to assess if there 
were differences in OPISM, OPCCM, and PIPVI by PII (low vs. high). Results of the ANOVA 
for OPISM by PII collection were not significant, F(1, 58) = 0.42, p = 0.517, partial η2 = 0.01.  
Results of the ANOVA for OPCCM by PII were also not significant, F(1, 58) = 0.68, p = 0.412, 
partial η2 = 0.01. Finally, results of the ANOVA for PIPVI by PII collection were not significant, 
F(1, 58) = 0.05, p = 0.819, partial η2 = 0.00. This suggests that no significant differences were 
found in OPISM, OPCCM, and PIPVI based upon the level of PII collected.  
 
To examine the three hypotheses, the Spearman correlations, non-parametric measures, were 
used for the differences between DPPM, OPISM, OPCCM and PIPVI with number of 
employees, annual revenue, and years in existence. OPISM scores differed significantly 
negatively to annual revenue and positively to years in existence. These scores suggest that as the 
annual revenue of the company increased, fewer OPIS violations occurred. Surprisingly, as years 
in existence increased, the more OPIS violations occurred. For PIPVI, the scores differed 
significantly negatively to both annual revenue and number of employees. This suggests that as 
annual revenue and number of employees increased, the PIPVI scores tended to decrease, which 
insinuates fewer personal information violations. No other significant differences were found. 
Because of these significant differences, the ANOVAs for OPISM and PIPVI were re-conducted 
as ANCOVAs to assess if controlling for annual revenue and years in existence affects the 
outcome of the comparisons. The results of the ANCOVA for OPISM scores by condition type 
after controlling for annual revenue and years in existence were significant, F(1, 96) = 5.74, p = 
0.019, partial η2 = 0.06. This is a change from the original ANOVA conducted, and the mean for 
chronic conditions was significantly higher than the mean for non-chronic conditions. The results 
of the ANCOVA for OPISM scores by registration type were not significant, F(1, 96) = 0.26, p = 
0.611, partial η2 = 0.00, which is similar to the previous results. The results for the ANCOVA for 
OPISM scores by headquarters country/region were not significant, F(3, 94) = 0.24, p = 0.865, 
partial η2 = 0.01, mirroring what was previously found.   
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Figure 3: Measures Contributions to PIPVI by Headquarters Country/Region 
 
The results of the ANCOVA for PIPVI scores by condition type while controlling for annual 
revenue showed significance, F(1, 97) = 7.79, p = 0.006, partial η2 = 0.07, suggesting that the 
PIPVI scores for chronic conditions were significantly lower than the PIPVI scores for non-
chronic conditions. This is similar to the results found in the original ANOVA. Significance was 
also found by registration type, F(1, 97) = 4.64, p = 0.034, partial η2 = 0.05, also mirroring the 
results found in the previous ANOVA. Finally, the results for differences by headquarters 
country/region were also similar to the previous ANOVA, F(3, 95) = 6.87, p < 0.001, partial η2 = 
0.18.  Thus, from the results of the ANCOVAs, the only change that was made by controlling for 
the relevant covariates was the ANCOVA for OPISM scores by condition type. Before, the 
ANOVA results were not significant, but after controlling for registration type and annual 
revenue, significant differences in OPISM scores were found by condition type. Based upon 
these results, the null hypotheses two and three were rejected, as a significant difference was 
found when controlling for annual revenue and years in existence. However, because there was 
no significant difference found for DPPPM, OPISM, OPCCM, or PIPVI, hypothesis one was 
accepted. Figure 3 presents the contributions of DPPPM, OPISM, and OPCCM to PIPVI by 
headquarters country/region.  
Discussions and Conclusions 
Because incidents continue to rise due to companies’ misuse of consumer information (Anton et 
al., 2010; Lanier & Saini, 2008; Pollach, 2007), our research study attempted to address the 
proliferation of online privacy violations by companies. We did so by developing a PIPVI 
benchmarking instrument, including its essential hierarchical components to assess documented 
and online practices implemented on Websites. This research study achieved the eight research 
questions and three hypotheses with a three-phased approach. First, an expert panel using the 
Delphi expert methodology was used to develop the documented practices of the privacy policy 
measure (DPPPM), online practices of information sharing measure (OPISM), online practices 
of consumer control measure (OPCCM), and the Personal Information Privacy Violations Index 
(PIPVI). Second, the PIPVI hierarchical benchmarking instrument was used to assess the 
documented and online practices implemented from 100 Website registrations of pharmaceutical 
companies that market chronic and non-chronic prescription medications. Last, a comparison 
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report was developed for Websites of pharmaceutical companies that market chronic and non-
chronic prescription medications.  
 
Overall the results indicated that pharmaceutical companies with headquarters in Europe had 
fewer personal information privacy violations than the US. In addition, the results suggested that 
first, as the annual revenue of the company increased, OPIS violations decreased. Second, as 
years in existence increased, the more OPIS violations occurred.  Third, the results suggested 
that fewer personal information privacy violations occur for chronic conditions than for non-
chronic conditions. Third, fewer violations occur with Website registrations for updates than for 
discounts. Fourth, as annual revenue and number of employees increased, the PIPVI scores 
tended to decrease, which insinuates fewer personal information violations. Finally, both Europe 
and UK demonstrated more overall adherence to the FIPs than the US and Asia. This suggests 
that self-regulation may not be sufficient, while more enforcement may be necessary to decrease 
personal information privacy violations.  
 
As with any research study, this one also had some limitations. One of the main significant 
limitations of our study is the generalizable of the specific index values (not the weights) due to 
the sample used. We expect that the Delphi compositions of the hierarchical weights will be 
indeed generalized in the future, but as time progresses or the use of the hierarchical 
benchmarking index on different companies may yield different values. While the sample size of 
100 Website registrations is valid, further studies can use a larger sample size to increase 
validation of the results and generalizability. Next, there was not an equal distribution of 
pharmaceutical company Website registrations across each headquarters country/region.  
Furthermore, because some of the Website registrations did not receive any emails, OPIS could 
not be truly assessed for all pharmaceutical companies Website registrations. Finally, because 
most pharmaceutical companies noted to submit request for personal information through email, 
phone, or mail, the delete practices could not be fully assessed.  
 
Recommendations and Future Research 
This research study outlined the research plan to develop a set of measures and a single 
composite index based upon hierarchical criteria identified by current US laws and regulations 
recommended for ethical business practices for online transactions. The weights of the 
hierarchical criteria and composite index were developed using a Delphi approach. We then 
carried out the actual development of the PIPVI, collected, and analyzed the data following the 
research outline plan discussed here. The findings and the results of the statistical analyses were 
reported as well. Future studies are warranted to increase the validity of the instrument. In 
addition, more research will be needed to expand the sample size and the use of other industries 
to increase the generalizability. While our work concentrated on the pharmaceutical market, 
future research could include assessing other industries. Moreover, future work can assess the 
opt-out practices against the Controlling the Assault of Non-Solicited Pornography and 
Marketing Act (CAN-SPAM Act). An extension of assessing the opt-out practices could include 
examining the differences based upon the type of request such as Website or email. Another area 
of future research includes selection of a population with criteria specifically for males and 
females or age to determine if the documented and online practices of companies differ by 
Online Journal of Applied Knowledge Management 
A Publication of the International Institute for Applied Knowledge Management 
Volume3, Issue 2, 2015 
 
 
83 
 
gender or age. Another area of future research includes having an equal distribution of Website 
registrations across each headquarters country/region. Finally, because the privacy policies stated 
that requests to delete information must be submitted by phone, email, or mail, future research 
could include assessing the delete practices by pharmaceutical companies or other industries. 
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